AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16115336 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish meat diet (60 g of pork meat)
Number of subjects: 19
Study 16115336 — intervention group
Group type: EXPERIMENTAL
Intervention: Polish meat diet (60 g of pork meat)
Number of subjects: 19
Study 16115336 — intervention group
Group type: COMPARATOR
Intervention: Vegetarian diet
Number of subjects: 19
Study 11832527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (goals of at least 7% weight loss and at least 150 minutes of physical activity per week)
Number of subjects: 3234
Study 11832527 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (850 mg twice daily)
Number of subjects: 3234
Study 11832527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 10026394 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation at low dose (20 J/cm2)
Number of subjects: 0
Study 10026394 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation at high dose (60 J/cm2)
Number of subjects: 0
Study 10026394 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA irradiation (both doses)
Number of subjects: 0
Study 7473528 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphoramidon (combined inhibitor of endothelin converting enzyme and neutral endopeptidase)
Number of subjects: 0
Study 7473528 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiorphan (selective inhibitor of NEP)
Number of subjects: 0
Study 7473528 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (selective ETA receptor antagonist)
Number of subjects: 0
Study 2263574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamphlet plus notification letter
Number of subjects: 161
Study 2263574 — intervention group
Group type: COMPARATOR
Intervention: Notification letter only
Number of subjects: 161
Study 6995038 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 0
Study 6995038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30628483 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based exercise programme with psychological intervention to change SPA (n=46)
Number of subjects: 84
Study 30628483 — intervention group
Group type: COMPARATOR
Intervention: Group-based exercise programme without psychological intervention to change SPA (n=38)
Number of subjects: 84
Study 30628483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (n=84)
Number of subjects: 84
Study 30022753 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTPO + DXM treatment
Number of subjects: 58
Study 30022753 — intervention group
Group type: COMPARATOR
Intervention: DXM treatment
Number of subjects: 58
Study 27553827 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen alone
Number of subjects: 117
Study 27553827 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide plus oxygen
Number of subjects: 117
Study 27553827 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole plus oxygen
Number of subjects: 117
Study 25123172 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation ON
Number of subjects: 0
Study 25123172 — intervention group
Group type: COMPARATOR
Intervention: Sacral neuromodulation OFF
Number of subjects: 0
Study 22380743 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-warfarin
Number of subjects: 72
Study 22380743 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-warfarin
Number of subjects: 72
Study 22380743 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein binding of (R)- and (S)-warfarin
Number of subjects: 72
Study 19419364 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg/kg
Number of subjects: 105
Study 19419364 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg/kg
Number of subjects: 105
Study 19419364 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 105
Study 17213239 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive therapy (standing on the fractured limb and walking in parallel bars)
Number of subjects: 20
Study 17213239 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (immobilization under skin traction and gradual use of a wheelchair)
Number of subjects: 20
Study 16094658 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release (VXR)
Number of subjects: 3097
Study 16094658 — intervention group
Group type: COMPARATOR
Intervention: Conventional antidepressants (CA)
Number of subjects: 3097
Study 11244392 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused short-term group therapy (10 sessions of 1.5 hours per week)
Number of subjects: 14
Study 11244392 — intervention group
Group type: COMPARATOR
Intervention: Control group (received group therapy 5 months after the first group)
Number of subjects: 14
Study 9227716 — intervention group
Group type: EXPERIMENTAL
Intervention: PGD2
Number of subjects: 20
Study 9227716 — intervention group
Group type: COMPARATOR
Intervention: Oxitropium bromide (200 micrograms)
Number of subjects: 20
Study 9227716 — intervention group
Group type: COMPARATOR
Intervention: Pre-inhalation of LTD4
Number of subjects: 20
Study 9227716 — intervention group
Group type: COMPARATOR
Intervention: Pre-inhalation of methacholine
Number of subjects: 20
Study 7678684 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5 mg b.i.d. titrated to 75 mg)
Number of subjects: 23
Study 7678684 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil SR (120 mg q.d. titrated to 360 mg)
Number of subjects: 23
Study 7678684 — intervention group
Group type: COMPARATOR
Intervention: Captopril (compared to placebo)
Number of subjects: 23
Study 7678684 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (compared to placebo)
Number of subjects: 23
Study 2889081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular recombinant alpha 2‐interferon (r‐IFN) ('Roferon') 10 X 10(6) IU/m2 thrice weekly for 12 weeks
Number of subjects: 24
Study 2889081 — intervention group
Group type: COMPARATOR
Intervention: Vitamin B complex
Number of subjects: 24
Study 28521579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) - 8 weekly sessions
Number of subjects: 15
Study 28521579 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 15
Study 28011513 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumescent Anesthesia (TA)
Number of subjects: 30
Study 28011513 — intervention group
Group type: COMPARATOR
Intervention: Control (no Tumescent Anesthesia)
Number of subjects: 30
Study 25579466 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation (two nights of delayed bedtime and four hours sleep)
Number of subjects: 33
Study 25579466 — intervention group
Group type: COMPARATOR
Intervention: Nine hours sleep (control group)
Number of subjects: 33
Study 23705645 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index (LGI) diet
Number of subjects: 77
Study 23705645 — intervention group
Group type: COMPARATOR
Intervention: Conventional Healthy Dietary Recommendation (CHDR)
Number of subjects: 77
Study 21131377 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA OP
Number of subjects: 303
Study 21131377 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA
Number of subjects: 303
Study 21131377 — intervention group
Group type: EXPERIMENTAL
Intervention: GPA2
Number of subjects: 303
Study 19399268 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix 0.25 mg/day) until the day of hCG administration (Group A, 66 cycles)
Number of subjects: 65
Study 19399268 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix 0.25 mg/day) until the day before hCG administration (Group B, 26 cycles)
Number of subjects: 65
Study 19399268 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 65
Study 16890670 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg toremifene
Number of subjects: 514
Study 16890670 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg toremifene
Number of subjects: 514
Study 16890670 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg toremifene
Number of subjects: 514
Study 16890670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 514
Study 14728938 — intervention group
Group type: EXPERIMENTAL
Intervention: HIT-91 therapy
Number of subjects: 0
Study 14728938 — intervention group
Group type: COMPARATOR
Intervention: Benign brain tumours (BBT)
Number of subjects: 0
Study 11560163 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.005% calcipotriol ointment
Number of subjects: 10
Study 11560163 — intervention group
Group type: COMPARATOR
Intervention: 5% coal tar ointment
Number of subjects: 10
Study 8811478 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Widman flap surgery
Number of subjects: 46
Study 8811478 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic metronidazole
Number of subjects: 46
Study 8811478 — intervention group
Group type: COMPARATOR
Intervention: Supplementary surgery or chemotherapy
Number of subjects: 46
Study 8811478 — intervention group
Group type: COMPARATOR
Intervention: Complex therapy
Number of subjects: 46
Study 1529416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil 12.5 mg
Number of subjects: 14
Study 1529416 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinacidil 25 mg
Number of subjects: 14
Study 1529416 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 14
Study 1529416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 3908727 — intervention group
Group type: EXPERIMENTAL
Intervention: S6472 (750 mg, 2 times/day)
Number of subjects: 388
Study 3908727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (CCL) (500 mg, 3 times/day)
Number of subjects: 388
Study 3908727 — intervention group
Group type: COMPARATOR
Intervention: Cephalexin (CEX) (500 mg, 4 times/day)
Number of subjects: 388
Study 30675739 — intervention group
Group type: EXPERIMENTAL
Intervention: levomilnacipran ER (40, 80, or 120 mg/d)
Number of subjects: 644
Study 30675739 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 644
Study 30675739 — intervention group
Group type: EXPERIMENTAL
Intervention: levomilnacipran ER
Number of subjects: 644
Study 29532981 — intervention group
Group type: EXPERIMENTAL
Intervention: HAM-RS2
Number of subjects: 46
Study 29532981 — intervention group
Group type: COMPARATOR
Intervention: Wheat-flour (Control)
Number of subjects: 46
Study 27494037 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (Met)
Number of subjects: 52
Study 27494037 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (Fen)
Number of subjects: 52
Study 25363118 — intervention group
Group type: EXPERIMENTAL
Intervention: Reality therapy
Number of subjects: 60
Study 25363118 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 60
Study 23102380 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin + Gp IIb/IIIa inhibitor (tirofiban)
Number of subjects: 101
Study 23102380 — intervention group
Group type: COMPARATOR
Intervention: UFH + Gp IIb/IIIa inhibitor (tirofiban)
Number of subjects: 101
Study 20954776 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 0
Study 20954776 — intervention group
Group type: COMPARATOR
Intervention: Individual therapy (IT)
Number of subjects: 0
Study 18853560 — intervention group
Group type: EXPERIMENTAL
Intervention: Masking by noise
Number of subjects: 2
Study 18853560 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracontrast and metacontrast masking
Number of subjects: 2
Study 16519386 — intervention group
Group type: COMPARATOR
Intervention: Standard Propofol (average particle size 193.3 nm) with 2 ml NaCl 0.9%
Number of subjects: 388
Study 16519386 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Propofol (average particle size 193.3 nm) with 2 ml lidocaine 2%
Number of subjects: 388
Study 16519386 — intervention group
Group type: EXPERIMENTAL
Intervention: Small particle size lipid emulsion of Propofol (Anepol: average particle size 140.5 nm) with 2 ml NaCl 0.9%
Number of subjects: 388
Study 16519386 — intervention group
Group type: EXPERIMENTAL
Intervention: Small particle size lipid emulsion of Propofol (Anepol: average particle size 140.5 nm) with 2 ml lidocaine 2%
Number of subjects: 388
Study 12627214 — intervention group
Group type: EXPERIMENTAL
Intervention: Urethral catheter removal on postoperative day (POD) 3
Number of subjects: 22
Study 10356941 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplement (Vitality Roeder 2000 Junior)
Number of subjects: 40
Study 10356941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7644858 — intervention group
Group type: EXPERIMENTAL
Intervention: High titre vaccines
Number of subjects: 0
Study 1487546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 28
Study 1487546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein meal
Number of subjects: 28
Study 1487546 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate meal
Number of subjects: 28
Study 4030162 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning dose (7:00 a.m.)
Number of subjects: 16
Study 4030162 — intervention group
Group type: COMPARATOR
Intervention: Evening dose (7:00 p.m.)
Number of subjects: 16
Study 29747311 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB)
Number of subjects: 40
Study 29747311 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB) as first-line therapy
Number of subjects: 40
Study 29747311 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB) as non-first-line therapy
Number of subjects: 40
Study 29747311 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB) in taxane-naïve patients
Number of subjects: 40
Study 29747311 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel for injection (albumin bound) (PAB) in taxane-pretreated patients
Number of subjects: 40
Study 29747311 — intervention group
Group type: COMPARATOR
Intervention: Abraxane (reference drug)
Number of subjects: 40
Study 26801885 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 40
Study 26801885 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic mucosal resection (EMR)
Number of subjects: 40
Study 23740477 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg/day Eleutherococcus senticosus root extract (ES)
Number of subjects: 144
Study 23740477 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-day professional stress management training (SMT)
Number of subjects: 144
Study 23740477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both (COM)
Number of subjects: 144
Study 23740477 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 144
Study 21123766 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 40 mg/day
Number of subjects: 22
Study 19652945 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (0.8 g kg(‐1) day(‐1))
Number of subjects: 112
Study 19652945 — intervention group
Group type: COMPARATOR
Intervention: Normal-protein diet (1.2 g kg(‐1) day(‐1))
Number of subjects: 112
Study 17960012 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF (docetaxel and cisplatin on day 1; fluorouracil by continuous infusion, days 1 to 5)
Number of subjects: 358
Study 17960012 — intervention group
Group type: COMPARATOR
Intervention: PF (cisplatin and fluorouracil every 3 weeks for four cycles)
Number of subjects: 358
Study 17960012 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 358
Study 17960012 — intervention group
Group type: COMPARATOR
Intervention: PF
Number of subjects: 358
Study 15476608 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2082
Study 15476608 — intervention group
Group type: COMPARATOR
Intervention: Balloon Angioplasty
Number of subjects: 2082
Study 15476608 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 2082
Study 15476608 — intervention group
Group type: COMPARATOR
Intervention: Control (no abciximab)
Number of subjects: 2082
Study 15476608 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Thrombosis
Number of subjects: 2082
Study 15476608 — intervention group
Group type: EXPERIMENTAL
Intervention: Major Adverse Cardiac Events
Number of subjects: 2082
Study 12170929 — intervention group
Group type: EXPERIMENTAL
Intervention: Kato-Katz technique for STH prevalence assessment
Number of subjects: 0
Study 9294786 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational seminars on skin cancer control (two 1-hour sessions)
Number of subjects: 82
Study 9294786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 82
Study 8373716 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg twice daily for 3 days
Number of subjects: 6
Study 8373716 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 25 mg twice daily
Number of subjects: 6
Study 8373716 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 3456816 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (PGD2) co-injected with histamine (2.5 nmol) at varying molar ratios (15 to 1215)
Number of subjects: 0
Study 3456816 — intervention group
Group type: COMPARATOR
Intervention: Histamine (2.5 nmol)
Number of subjects: 0
Study 31402740 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 120
Study 31402740 — intervention group
Group type: EXPERIMENTAL
Intervention: IFC
Number of subjects: 120
Study 31402740 — intervention group
Group type: EXPERIMENTAL
Intervention: Aussie current
Number of subjects: 120
Study 31402740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31402740 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS, IFC, Aussie current
Number of subjects: 120
Study 30156192 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek‐Z550 (3M/ESPE) with Adper™ Single Bond 2 (3M/ESPE) etch and rinse adhesive
Number of subjects: 23
Study 30156192 — intervention group
Group type: COMPARATOR
Intervention: Charisma‐Diamond (Heraeus Kulzer) with Gluma2 Bond (Heraeus Kulzer) etch and rinse adhesive
Number of subjects: 23
Study 28033693 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine suppository (10 mg)
Number of subjects: 100
Study 28033693 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac suppository (100 mg)
Number of subjects: 100
Study 24199687 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (n=36)
Number of subjects: 108
Study 24199687 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate supplementation (n=36)
Number of subjects: 108
Study 24199687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=36)
Number of subjects: 108
Study 23296213 — intervention group
Group type: EXPERIMENTAL
Intervention: CM(attendance)
Number of subjects: 30
Study 23296213 — intervention group
Group type: EXPERIMENTAL
Intervention: CM(weight)
Number of subjects: 30
Study 23296213 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 30
Study 23296213 — intervention group
Group type: EXPERIMENTAL
Intervention: CM(behavior)
Number of subjects: 30
Study 21330809 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training (SBT)
Number of subjects: 27
Study 21330809 — intervention group
Group type: COMPARATOR
Intervention: Traditional tutorial-based interactive education training (IET)
Number of subjects: 27
Study 18712029 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate lotion 0.05%
Number of subjects: 20
Study 18712029 — intervention group
Group type: COMPARATOR
Intervention: OTC anti‐itch preparation containing benzyl alcohol
Number of subjects: 20
Study 18712029 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum ointment
Number of subjects: 20
Study 15969892 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (up to 800 mg/day)
Number of subjects: 403
Study 15969892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 403
Study 14513648 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin 0.1 mg subcutaneously daily for 7 days starting on day 21 of menstrual cycle
Number of subjects: 120
Study 14513648 — intervention group
Group type: COMPARATOR
Intervention: Buserelin intranasal spray (long protocol)
Number of subjects: 120
Study 10371363 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-community health worker team in combination with usual medical care (SI)
Number of subjects: 204
Study 10371363 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UC) alone
Number of subjects: 204
Study 11324828 — intervention group
Group type: EXPERIMENTAL
Intervention: NASBA assay
Number of subjects: 24
Study 11324828 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplicor assay
Number of subjects: 24
Study 1960249 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-containing varnish
Number of subjects: 51
Study 1960249 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 51
Study 1960249 — intervention group
Group type: COMPARATOR
Intervention: Prophylaxis alone
Number of subjects: 51
Study 6816316 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of endocrine and chemical therapies
Number of subjects: 0
Study 6816316 — intervention group
Group type: COMPARATOR
Intervention: Endocrine therapy
Number of subjects: 0
Study 6816316 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study 30712804 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus fulvestrant
Number of subjects: 0
Study 30712804 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant
Number of subjects: 0
Study 28686808 — intervention group
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy Oral Health Promotion intervention (two 15-minute skills-based educational modules)
Number of subjects: 101
Study 28686808 — intervention group
Group type: COMPARATOR
Intervention: Standard CenteringPregnancy prenatal care
Number of subjects: 101
Study 26668436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based intervention (mHealth) comprising six automated, interactive voice messages with counsellor phone support.
Number of subjects: 500
Study 26668436 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 500